Value of digoxin in heart failure and sinus rhythm: New features of an old drug?

Journal of the American College of Cardiology

Volumn 28, Issue 4, 1996, Pages 813-819

  Van Veldhuisen, Dirk J ^a   De Graeff, Pieter A ^a   Remme, Willem J ^a   Lie, K I ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIGITALIS; DIGOXIN;

ARTICLE; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; EXERCISE TOLERANCE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; SINUS RHYTHM; TREATMENT OUTCOME; UTILIZATION REVIEW;

EID: 0030273066     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(96)00247-1     Document Type: Review

References (99)

1. Withering W. An Account of the Foxglove, and some of its Medical Uses: with Practical Remarks on Dropsy, and other Diseases. London: GGJ and J Robinson, 1785:232-52.
2. Gheorghiade M. A Symposium: Management of heart failure in the 1990s: a reassessment of the role of digoxin therapy. Introduction. Am J Cardiol 1992;69:1G-3G.
3. De Bono D. Digoxin in eurhythmic heart failure: PROVED or "not proven"? [editorial]. Lancet 1994;343:128-9.
4. Parmley WW. Should digoxin be the drug of choice after diuretics in chronic congestive heart failure? Introduction. J Am Coll Cardiol 1988;12:265-7.
5. Poole-Wilson PA. Digitalis: dead or alive? Cardiology 1988;75(Suppl 1): 103-9.
6. Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle MG Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation. 80:1989;65-77.
7. Gheorghiade M, Ferguson D. Digoxin. A neurohumoral modulator in heart failure? Circulation 1989;84:2181-6.
8. The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988;259:539-44.
9. The German and Austrian Xamoterol Study Group. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. Lancet 1988;1:489-93.
10. DiBianco R, Shabetai R, Kostuk W, et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989;320:677-83.
11. Packer M, Gheorghiade M, Young JBet al. for the RADIANCE Study. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med. 329:1993;1-7.
12. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK, on behalf of the PROVED Investigative Group. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED Trial. J Am Coll Cardiol 1993;22:955-62.
13. Poole-Wilson PA. Digoxin withdrawal in patients with heart failure [letter] J Am Coll Cardiol 1994;24:578-82.
14. Packer M. The neurohumoral hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
15. Tuininga YS, Van Veldhuisen DJ, Brouwer J, et al. Heart rate variability in left ventricular dysfunction and heart failure: effects and implications of drug treatment. Br Heart J 1994;72:509-13.
16. Cohen JN. Management of chronic heart failure. N Engl J Med 1996;335: 490-8.
17. Remme WJ. Therapeutic strategies and neurohumoral control in heart failure. Eur Heart J 1994;15 Suppl D:129-38.
18. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A, for the V-HeFT VA Cooperative Studies Group. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. Circulation 1993;87 Suppl VI:VI-40-8.
19. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990;82:1730-6.
20. Cohn JN. Inotropic therapy for heart failure: paradise postponed. N Engl J Med 1989;320:729-31.
21. Remme WJ. Inotropic agents for heart failure: what if digoxin increases mortality? Br Heart J 1994;72 Suppl:92-9.
22. Katz AM. Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation 1986;73 Suppl III:III-184-8.
23. Packer M. The development of positive inotropic agents for chronic heart failure: how have we gone astray? J Am Coll Cardiol 1993;22 Suppl A:119A-26A.
24. Mason DT, Braunwald E. Studies on digitalis: X. Effects of ouabain on forearm vascular resistance and venous tone in normal subjects and patients with heart failure. J Clin Invest 1964;43:532-43.
25. van Veldhuisen DJ, Man in 't Veld AJ, Dunselman PHJM, et al. Doubleblind, placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: Results of the Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol 1993;22:1564-73.
26. Watanabe AM Digitalis and the autonomic nervous system. J Am Coll Cardiol. 5(Suppl A):1985;35A-42A.
27. Ferguson DW Digitalis and neurohormonal abnormalities in heart failure and implications for therapy. Am J Cardiol. 69:1992;24G-33G.
28. Goldsmith SR, Simon AB, Miller E. Effect of digitalis on norepinephrine kinetics in congestive heart failure. J Am Coll Cardiol 1992;20:858-63.
29. Ribner HS, Plucinski DA, Hsieh AMet al. Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due to dilated cardiomyopathy: a hemodynamic-hormonal study. Am J Cardiol. 56:1985;896-904.
30. Gheorghiade M, Hall V, Lakier JB, Goldstein S. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with heart failure. J Am Coll Cardiol 1989;13:134-42.
31. van Veldhuisen DJ, Brouwer J Man in 't Veld AJ, Dunselman PHJM, Boomsma F, Lie KI. Progression of mild untreated heart failure during 6 months follow-up and clinical and neurohumoral effects of ibopamine and digoxin as monotherapy. Am J Cardiol. 75:1995;796-800.
32. Covit AB, Schaer GL, Sealy JE, Laragh JH, Cody RJ. Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure. Am J Med 1983;75:445-7.
33. +-ATP-ase in the regulation of sodium excretion under normal conditions and in acute congestive heart failure. Circulation 1992;85:1912-7.
34. Thames MD Acethylstrophantidin-induced reflex inhibition of canine renal sympathetic nerve activity mediated by cardiac receptors with vagal afferents. Circ Res. 44:1979;8-15.
35. Bloch KD, Zmir N, Lichtstein D, Seidman CE, Seidman JG. Ouabain induces secretion of pro-atrial natriuretic factor in rat cardiac cardiocytes. Am J Physiol 1988;255:E383-7.
36. Gheorghiade M, Hall VB, Fenn NM, Goldstein S Chronic effects of digoxin withdrawal on neurohormones in patients with stable heart failure treated with converting enzyme inhibitors [abstract]. Eur Heart J. 14(Abstract Suppl):1993;131.
37. Gillis RA, Quest JA The role of the nervous system in the cardiovascular effects of digitalis. Pharmacol Rev. 31:1980;19-97.
38. Ferrari A, Gregorini L, Ferrari MC, Preti L, Mancia G. Digitalis and baroreceptor reflexes in man. Circulation 1981;63:279-85.
39. Ferrari A, Bonazzi O, Gregorini L, Gardumi M, Perondi R, Mancia G. Modification of the baroreceptor control of atrioventricular conduction induced by digitalis in man. Cardiovasc Res 1983;17:633-41.
40. Ferguson DW, Abboud FM, Mark AL. Selective impairment of baroreflex-mediated vasoconstrictor responses in patients with ventricular dysfunction. Circulation 1984;69:451-60.
41. Imamura T, Takeshita A, Ashihara T, Yamamoto K, Hoka S, Nakamura M. Digitalis-induced augmentation of cardiopulmonary baroreflex control of forearm vascular resistance. Circulation 1985;71:11-6.
42. Hirsch AT, Dzau VJ, Creager MA Baroreceptor function in congestive heart failure: effect on neurohumoral activation and regional vascular resistance. Circulation. 75(Suppl IV:IV):1987;36-48.
43. Krum H. Bigger JT, Goldsmith RL, Packer M. Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. J Am Coll Cardiol 1995;25:289-94.
44. Brouwer J, van Veldhuisen DJ, Man in 't Veld AJ, et al. Heart rate variability in patients with mild to moderate heart failure: effects of neurohumoral modulation by digoxin and ibopamine. J Am Coll Cardiol 1995;26:983-90.
45. Kaufman ES, Bosner MS, Bigger JT, et al. Effects of digoxin and enalapril on heart rate variability and response to head-up tilt in normal subjects. Am J Cardiol 1993;72:95-9.
46. Brouwer J, van Veldhuisen DJ Man in 't Veld AJ, Dunselman PHJM, Haaksma J, Lie KI. Circadian pattern of heart rate variability in heart failure is progressively disturbed with increasing neurohumoral activation [abstract]. J Am Coll Cardiol. 23(Suppl A):1994;392A.
47. Kimmelstiel C, Benotti JR. How effective is digitalis in the treatment of congestive heart failure? Am Heart J 1988;116:1063-70.
48. Parmley WW. Pathophysiology and current therapy of congestive heart failure. J Am Coll Cardiol 1989;13:771-85.
49. Smith TW. Digitalis. Mechanisms of action and clinical use. N Engl J Med 1988;318:358-65.
50. Lee DC, Johnson RA, Bingham JBet al. Heart failure in outpatients: a randomized trial of digoxin versus placebo. N Engl J Med. 306:1982;4-9.
51. Guyatt GH, Sullivan MJ, Fallen EL, et al. A controlled trial of digoxin in congestive heart failure. Am J Cardiol 1988;61:371-5.
52. Arnold SB, Byrd RC, Meister W, et al. Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med 1980;303:1443-8.
53. Theorghiade M, StClair J, StClair C, Beller GA. Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators. J Am Coll Cardiol 1987;9:849-57.
54. Fleg JL, Gottlieb SH, Lakatta EG. Is digoxin really important in treatment of compensated heart failure? A placebo-controlled crossover study in patients with sinus rhythm. Am J Med 1982;73:244-50.
55. Fleg JH, Rothfeld B, Gottlieb SH, Wright J. Effects of maintenance digoxin on aerobic performance and exercise left ventricular function in mild to moderate heart failure due to coronary artery disease: a randomized, placebo-controlled, crossover trial. J Am Coll Cardiol 1991;17:743-51.
56. Kelly RA, Smith TW. Digoxin in heart failure: implications of recent trials. J Am Coll Cardiol 1993;22 Suppl A:107A-12A.
57. Jaeschke R, Oxman AD, Guyatt GH. To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systemic overview and meta-analysis Am J Med 1990;88:279-86.
58. Gheorghiade M, Zarowitz BJ Review of randomized trials of digoxin therapy in patients with chronic heart failure. Am J Cardiol. 69:1992;48G-63G.
59. Just H, Drexler H, Taylor SH, Siegrist J, Schulgen G, Schumacher M, for the CADS Study Group. Captopril versus digoxin in patients with coronary artery disease and mild heart failure. A prospective, double-blind, placebo-controlled multicenter study. Herz 1993;18 Suppl 1:436-43.
60. Kleber FX, Thyroff-Friesinger U Ibopamine versus digoxin in the treatment of mild congestive heart failure. Cardiology. 77(Suppl 5):1990;75-80.
61. Tauke J, Goldstein S, Gheorghiade M Digoxin for chronic heart failure: a review of the randomized controlled trials with special attention to the PROVED and RADIANCE Trials. Prog Cardiovasc Dis. 37:1994;49-58.
62. Bigger JT, Fleiss JL, Rolnitzky LM, Merab JP, Ferrick KJ. Effect of digitalis on survival after myocardial infarction. Am J Cardiol 1985;55:623-30.
63. PROMISE Investigators and Coordinators, Mancini DM, Benotti JR, Elkayam Uet al. Antiarrhythmic drug use and high serum levels of digoxin are independent adverse prognostic factors in patients with chronic heart failure [abstract]. Circulation. 84(Suppl II):1991;II-243.
64. Gheorghiade M, Hall VB, Jacobson G, Alam M, Rosman H, Goldstein S. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. Circulation 1995;92: 1801-7.
65. Hoeschen RJ, Cuddy TE. Dose-response relation between therapeutic levels of serum digoxin and systolic time intervals. Am J Cardiol 1975;35:469-72.
66. PROVED and RADIANCE Investigators, Young JB, Gheorghiade M, Packer Met al. Are low serum levels of digoxin effective in chronic heart failure? Evidence challenging the accepted guidelines for a therapeutic serum level of the drug [abstract]. J Am Coll Cardiol. 21(Suppl A):1993;378A.
67. Lewis RP Clinical use of serum digoxin concentrations. Am J Cardiol. 69:1992;97G-107G.
68. Smith TW, Antman EM, Friedman PL, Blatt CM, Marsch JD Digitalis glycosides: mechanisms and manifestations of toxicity. Prog Cardiovasc Dis. 27:1984;21-41.
69. Fisch C, Knoebel SB. Digitalis cardiotoxicity. J Am Coll Cardiol 1985;5:91A-8A.
70. Warren JL, McBean AM, Hass SL, Babish JD. Hospitalizations with adverse events caused by digitalis therapy among elderly Medicare beneficiaries. Arch Intern Med 1994;154:1482-7.
71. Kelly RA, Smith TW. Recognition and management of digitalis toxicity. Am J Cardiol 1992;69:108G-19G.
72. Ware JA, Snow E, Luchi JM, Luchi RJ. Effect of digoxin on ejection fraction in elderly patients with congestive heart failure. J Am Geriatr Soc 1984;32: 631-5.
73. Moss AJ, Davis HT, Conard DL, DeCamilla JJ, Odoroff CL. Digitalis-associated cardiac mortality after myocardial infarction. Circulation 1981;64: 1150-6.
74. Byington R, Goldstein S, for the BHAT Research Group. Association of digitalis therapy with mortality in survivors of acute myocardial infaction: observations in the Beta-blocker Heart Attack Trial. J Am Coll Cardiol 1985;6:976-82.
75. Yusuf S, Wittes J, Bailey K, Furberg C. Digitalis - a new controversy regarding an old drug. The pitfalls of inappropriate methods. Circulation 1986;73:14-8.
76. Køber L, Torp-Pedersen C, Gadsbøll N, Hildebrandt P, Høilund-Carlsen PF. Is digoxin an independent risk factor for long-term mortality after acute myocardial infarction? Eur Heart J 1994;15:382-8.
77. Goldstein RA, Passamani ER, Roberts R. A comparison of digoxin and dobutamine in patients with acute infarction and cardiac failure. N Engl J Med 1980;303:846-50.
78. Forrester J, Bezdek W, Chatterjee K, et al. Hemodynamic effects of digitalis in acute myocardial infarction. Ann Intern Med 1972;76:863-4.
79. Lipp H, Denes P, Gambetta M, et al. Hemodynamic response to acute intravenous digoxin in patients with recent myocardial infarction and coronary insufficiency with and without heart failure. Chest 1972;63:862-7.
80. Bonaduce D, Petretta M, Arrichiello P, et al. Effects of captopril treatment on left ventricular remodeling and function after anterior myocardial infarction: comparison with digitalis. J Am Coll Cardiol 1992;19:858-63.
81. Morrison J, Caromilas J, Robbins Met al. Digitalis and myocardial infarction in man. Circulation. 62:1980;8-16.
82. Marcus FI. Use of digitalis in acute myocardial infarction. Circulation 1980;62:17-9.
83. Rahimtoola SH, Gunnar RM. Digitalis in acute myocardial infarction: help or hazard? Ann Intern Med 1975;82:234-40.
84. Karliner JS, Braunwald E. Present status of digitalis treatment of acute myocardial infarction patients. Circulation 1972;45:891-6.
85. Covell JW, Braunwald E, Ross J, Sonnenblick E. Studies on digitalis XVI. Effects on myocardial oxygen consumption. J Clin Invest 1966;45:1535-42.
86. Gross GJ, Waltier DC, Hardman HF, Somani P. The effect of ouabain on nutritional circulation and regional myocardial blood flow. Am Heart J 1977;93:487-95.
87. Lynch JJ, Simpson PJ, Gallagher KP, McClanahan TB, Lee KA, Lucchesi BR. Increase in experimental infarct size with digoxin in a canine model of myocardial ischemia-reperfusion injury. Am Heart J 1988;115:1171-82.
88. Cohn JN, Tristani FE, Khatri IM Cardiac and peripheral vascular effects of digitalis in clinical cardiogenic shock. Am Heart J. 78:1969;318-330.
89. Pfeffer MA, Braunwald E, Moye LA, et al. The effect of captopril on mortality in patients with left ventricular dysfunction following myocardial infarction: results of the Survival and Ventricular Enlargement (SAVE) trial. N Engl J Med 1992;327:669-77.
90. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbility of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-7.
91. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-35.
92. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
93. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
94. Pitt B. Should digoxin be the drug of choice after diuretics in chronic congestive heart failure? Anatagonist's viewpoint. J Am Coll Cardiol 1988; 12:271-3.
95. Baker DW, Konstam MA, Bottorff M, Pitt B. Management of heart failure. I. Pharmacologic treatment. JAMA 1994;272:1361-6.
96. Yusuf S, Garg R, Held P, Gorlin R Need for a large randomized trial to evaluate the effects of digitalis on morbidity and mortality in congestive heart failure. Am J Cardiol. 69:1992;64G-70G.
97. Ward RE, Gheorghiade M, Young JB, Uretsky B Economic outcomes of withdrawal digoxin therapy in adult patients with stable congestive heart failure. J Am Coll Cardiol. 26:1995;93-101.
98. Uretsky BF Digoxin in the treatment of patients with chronic heart failure. Its place in therapy. Drugs Aging. 7:1995;1-9.
99. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.